LSE:GSK 16 February 2026 - 15 June 2026

GSK stock rises as £80 billion valuation shifts focus to oncology delivery
·

GSK stock rises as £80 billion valuation shifts focus to oncology delivery

GSK plc rose on Tuesday, but the more useful number for investors was not the one-day gain. It was the gap between the share price and the Street model. At 1901 BST, after the London Stock Exchange regular session that runs from 0800 to 1630 BST, Davy’s delayed feed showed GSK at 2,003p, up 20p, or 1.01%, with a 1,982p-2,031p day range. The FTSE 100 closed up 0.1% at 10,655.88 points.
July 7, 2026
GSK Trades Lower After Nuvalent Deal Raises Focus on Drug Pipeline, Approval Uncertainty
·

GSK Trades Lower After Nuvalent Deal Raises Focus on Drug Pipeline, Approval Uncertainty

GSK plc traded lower on Monday in London, shares at 1,976p at 11:01 BST, off 0.4%, with the market cap at about £80 billion. The move stood out, with most European stocks up—Reuters reported the STOXX 600 hit a record after talk of a U.S.-Iran deal pushed oil lower and drove risk appetite higher. When a stock drops on an up market, it’s usually got its own issues. For GSK, investors keep looking at capital use and how it handles drug development risks. No fresh earnings news hit this session. GSK’s plan to buy Nuvalent for $10.6 billion—$124 per share in cash—hangs over the stock. That’s a 40% premium to Nuvalent’s last close. Reuters said it’s GSK’s largest deal in
June 15, 2026
GSK shares gain after rare-disease win, oncology bet at $10.6 billion
·

GSK shares gain after rare-disease win, oncology bet at $10.6 billion

GSK plc closed up in London trade, with shares gaining 21.5p, or 1.10%, to a 1,980p sell price and 1,981p buy price by the Hargreaves Lansdown market close snapshot. The FTSE 100 finished up 1.63%. Investors looked past a new rare-disease regulatory update to focus on the bigger question: whether CEO Luke Miels can deliver durable earnings growth from an expanded oncology pipeline. GSK said June 12 that its drug momelotinib, already marketed as Ojjaara or Omjjara for myelofibrosis, was granted orphan drug status by both the US Food and Drug Administration and the European Medicines Agency for VEXAS syndrome. Orphan drug designation is a regulatory status aimed at drugs for rare diseases. The EMA says EU orphan designation gives
June 13, 2026
GSK up as rare-disease tag shines spotlight on $10.6bn oncology deal
·

GSK up as rare-disease tag shines spotlight on $10.6bn oncology deal

GSK plc shares traded up in London on Friday after another pipeline update from the UK drugmaker. At 12:24 London time, Sharecast quoted the stock 1.32% higher, or up 26p, while Hargreaves Lansdown’s delayed retail quotes pegged GSK at about 1,988p/1,989p. The move extends a rally that began after Thursday’s 2.13% gain, which beat a smaller FTSE 100 rise. GSK said momelotinib, marketed as Ojjaara/Omjjara for myelofibrosis, just got Orphan Drug Designation from the US FDA and the European Medicines Agency for VEXAS syndrome—a rare, life-threatening inflammatory and blood disorder with no drugs cleared for use. Orphan Drug Designation gives some incentives for making rare disease drugs, but it is not a green light to start selling for that use.
June 12, 2026
GSK Shares Gain After Arexvy Approval for More Adults in Japan
··

GSK stock steadies as $10.6bn Nuvalent deal turns focus to lung-cancer approvals

GSK plc shares steadied near midday Wednesday, trading at 1,905.5p, up 0.11%, after investors spent a day weighing the cost of its $10.6 billion cash deal for Nuvalent against the chance to add two late-stage lung-cancer medicines that could reach the U.S. market this year. The stock had fallen 0.5% on Tuesday after the acquisition was announced. The deal is the reason GSK is in focus. The London-listed drugmaker agreed to pay $124 a share in cash for Nuvalent, a Boston clinical-stage biotech, valuing the company at $10.6 billion, or $9.4 billion after cash acquired. The price is 40% above Nuvalent’s last close and 26% above its 30-day volume-weighted average price, a trading measure that reflects the average price investors
June 10, 2026
GSK Drops Even After New £45 Million Liver Drug Move
·

GSK Drops Even After New £45 Million Liver Drug Move

GSK plc was down nearly 1% in early afternoon trading Monday in London, trailing the UK blue-chips. A new liver-fibrosis research deal didn’t move investors off concerns about GSK’s pipeline. The stock traded at about 1,919.5 pence, off 0.95%. The main UK share index edged up 0.11%. The story is in focus now because GSK’s value depends more on whether new CEO Luke Miels can show the company has enough late-stage drugs to make up for losses from older products and meet long-term sales targets, not on one small research deal. Reuters said in April that Miels is under investor pressure over GSK’s 2031 revenue target and the 2028 patent loss for its HIV drug dolutegravir. James Eugene, research analyst
June 8, 2026
GSK Shares Gain After Arexvy Approval for More Adults in Japan
·

GSK edges past FTSE gain; what Friday’s move means now

GSK finished the week strong, jumping 1.89% to 1,938p on Friday as buyers stepped into UK pharma ahead of the weekend. The move outpaced the FTSE 100, which added just 0.07%. GSK shares remain 15.07% off the 52-week high of 2,282p set on Feb. 18. GSK heads into next week with momentum partly back after trading paused for the weekend, with shares finishing 3.00% higher over five days and up 6.22% since Jan. 1, based on MarketScreener data. The London market shut after Friday’s session.
June 6, 2026
GSK Shares Gain After Arexvy Approval for More Adults in Japan
····

GSK Shares Gain After Arexvy Approval for More Adults in Japan

GSK shares traded higher in London on Monday after Japan granted expanded approval for Arexvy, the company’s RSV vaccine. Investors got a new regulatory boost for vaccines as GSK also kept buying back its own shares. Shares traded at 1,879.81 pence, gaining 0.93%, after starting at 1,855.50p and reaching as high as 1,880.42p, market data show. The FTSE 100 was up 0.99% at 10,296.36.
May 18, 2026
GSK Stock Goes Ex-Dividend Today: Why the 17p Payout Comes With a Bigger Pipeline Test
····

GSK Shares Face Monday Test After Dividend Hit, China Drug Deal And Buyback

GSK’s shares slipped into the weekend, leaving Monday’s session as an early test of whether investors still want to buy the drugmaker after a China pipeline deal and a fresh buyback push, or whether the stock remains capped by dividend and earnings-quality concerns. The stock closed Friday at 1,862.5 pence, down 10p, or 0.53%, with the day’s range stretching from 1,855.5p to 1,899.5p. It was still up from 1,843p a week earlier, helped by a sharp Tuesday gain, but the move was not clean. Volume on Friday was 11.08 million shares, above several sessions earlier in the week.
May 16, 2026
GSK plc’s Jemperli Court Fight With AnaptysBio Takes New Turn Before July Trial
·····

GSK Plc Dividend Date Today: Why Its 2026 Payout Is Back in Focus

GSK’s U.S.-listed American depositary shares go ex-dividend on Friday, putting the British drugmaker’s next payout into live market focus. The company’s calendar lists May 15 as the ADS ex-dividend and record date for its first-quarter dividend, with payment due July 9; a market notice this week also flagged GSK among stocks going ex-dividend on May 15. Ex-dividend means new buyers after the cut-off no longer receive the next declared payout. That matters now because GSK is trying to keep its income case steady while asking investors to look harder at new drugs, not just the legacy strength of HIV medicines and vaccines.
May 15, 2026
GSK Stock Goes Ex-Dividend Today: Why the 17p Payout Comes With a Bigger Pipeline Test
····

GSK Stock Goes Ex-Dividend Today: Why the 17p Payout Comes With a Bigger Pipeline Test

GSK plc shares in London went ex-dividend on Thursday, locking in eligibility for the first-quarter payout just as the company aims to steer focus toward its pipeline. Investors buying on or after May 14 miss out on this round of dividends; GSK’s calendar puts the ex-dividend date on May 14, with the record date following on May 15 and the payment set for July 9. The timing here is key. GSK wants investors to weigh both reliable capital returns and its specialty medicines push at the same time. The group announced a 17 pence dividend for the first quarter, stuck to its projection for 70 pence in 2026, and reiterated expectations: 3% to 5% turnover growth and 7% to 9%
May 14, 2026
GSK’s China Hepatitis B Deal Puts £2 Billion Bepirovirsen Bet in Focus
·····

GSK’s China Hepatitis B Deal Puts £2 Billion Bepirovirsen Bet in Focus

GSK plc is pushing for wider access to bepirovirsen in China, locking in an exclusive deal with Chia Tai Tianqing Pharmaceutical, part of Sino Biopharmaceutical. With this move, the British pharma giant aims to turn its late-stage hepatitis B candidate into a serious growth engine. CTTQ is set to manage import, distribution, hospital access, and promotion across mainland China. GSK, for its part, keeps a grip on regulatory and medical strategy. Timing’s key here. Bepirovirsen is on the investor radar as GSK pushes to move past its traditional vaccine and HIV drug business, aiming to top £40 billion in yearly sales by 2031—a goal it stuck with after posting £7.6 billion for the first quarter. Last month, Chief Executive Luke
May 13, 2026
GSK Wins Court Ruling in Pfizer-BioNTech Covid Vaccine Patent Fight
······

GSK Wins Court Ruling in Pfizer-BioNTech Covid Vaccine Patent Fight

A U.S. federal judge has tossed Acuitas Therapeutics Inc.’s attempt to shield Pfizer and BioNTech’s Comirnaty Covid-19 vaccine from GSK’s patent claims, handing the British pharma giant a procedural victory in the ongoing mRNA legal fight. Judge Gregory B. Williams sided with GSK, dismissing the Acuitas case on grounds that the court lacked subject-matter jurisdiction—essentially, it didn’t have the authority to weigh in as presented, according to Bloomberg Law on Friday. The decision keeps the spotlight fixed on the main Delaware showdown involving GSK, Pfizer and BioNTech, instead of letting a supplier-driven lawsuit muddy the waters. Back in 2024, GSK filed suit against Pfizer and BioNTech, claiming Comirnaty stepped on patents for mRNA vaccine technology the company says it created
May 9, 2026
UK Stock Market Week Ahead: FTSE 100 Faces BoE Shock Test After First Weekly Loss in Five
········

UK Stock Market Week Ahead: FTSE 100 Faces BoE Shock Test After First Weekly Loss in Five

London’s stock market stays dark Sunday, but pressure is building for Monday’s open. The FTSE 100—fresh off its first weekly drop in five—faces a busy stretch, with Bank of England decisions and key earnings reports ahead. Trading on the London Stock Exchange runs 8:00 a.m. to 4:30 p.m. local, Monday through Friday. London’s FTSE 100 dropped 0.8% to end at 10,379.08 on Friday, with the FTSE 250 matching that 0.8% loss. Investors struggled with shaky U.S.-Iran relations, oil breaking above $100 a barrel, and a Bank of England warning that global equities might not be fully accounting for risk. Among the laggards: Barclays and HSBC slid, Wizz Air tumbled as pricier oil hammered airline shares, and AstraZeneca along with GSK
April 26, 2026
GSK’s Jemperli Court Fight Just Got Tougher Before Q1 Earnings
······

GSK’s Jemperli Court Fight Just Got Tougher Before Q1 Earnings

Tesaro, the GSK plc subsidiary, took a hit Friday when the Delaware Court of Chancery tossed out its claim that AnaptysBio had anticipatorily breached their Jemperli cancer-drug partnership. The court’s move leaves the door open for the larger licensing dispute to continue. It’s a tough moment for GSK. The drugmaker, listed in London, is set to release its first-quarter numbers on Wednesday, April 29, at 0700 BST. Investors want to see evidence that the company’s push into oncology and specialty drugs under Chief Executive Luke Miels is still driving growth.
April 25, 2026
GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake
·······

GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake

GSK plc wrapped up changes to ViiV Healthcare’s ownership structure on April 1. After Pfizer’s exit from the HIV-focused joint venture, Japan’s Shionogi bumped its stake up to 21.7%. GSK remains the majority owner with 78.3%, the company said. Timing is crucial here: ViiV is a core growth driver as GSK shifts focus toward specialty medicines. For 2025, GSK reported an 11% increase in HIV sales to 7.7 billion pounds, fueling a 17% jump in specialty medicines revenue.
April 2, 2026
GSK Stock Price Slips as Buyback Continues and Linerixibat Decision Looms
····

GSK Stock Price Slips as Buyback Continues and Linerixibat Decision Looms

GSK shares dropped 0.7% to 2,051 pence by 0946 GMT on Thursday, after the company announced fresh buybacks. London stocks were feeling the heat from resurging oil-fueled inflation jitters. According to a filing, GSK repurchased 513,409 shares on March 11, paying an average of 2,061.69 pence each. The new filing is a key move for GSK, which is working to prove it can keep delivering cash to shareholders even as CEO Luke Miels revamps the company’s drug pipeline. Shares surged to a multi-decade peak after February’s earnings, when Miels reaffirmed GSK’s long-term sales outlook. He also flagged the need for smaller acquisitions and quicker drug development if the company wants to offset looming patent expiries on its blockbuster HIV treatments
March 12, 2026
1 2